Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients | Zendy

Richard P. Wenzel | Zendy; A. Del Favero | Zendy; C C Kibbler | Zendy; Thomas R. Rogers | Zendy; Coleman Rotstein | Zendy; Josephine Mauskopf | Zendy; Stephen Morris | Zendy; Haran T. Schlamm | Zendy; Peter F. Troke | Zendy; A Marciniak | Zendy

Open Access

Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients

Author(s) -

Richard P. Wenzel,

A. Del Favero,

C C Kibbler,

Thomas R. Rogers,

Coleman Rotstein,

Josephine Mauskopf,

Stephen Morris,

Haran T. Schlamm,

Peter F. Troke,

A Marciniak

Publication year - 2005

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkh535

Subject(s) - voriconazole , medicine , aspergillosis , clinical trial , amphotericin b , randomized controlled trial , intensive care unit , surgery , intensive care medicine , emergency medicine , antifungal , dermatology , immunology

The objective of this study was to conduct an economic evaluation of voriconazole compared with conventional amphotericin B deoxycholate (CAB) using data from a recently reported randomized comparative trial in patients with various underlying immunosuppressive conditions. This trial demonstrated the superiority of voriconazole in terms of clinical response, survival and safety when used as primary therapy for invasive aspergillosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research